Core Viewpoint - The GLP-1 market is highly competitive, with Novo Nordisk and Eli Lilly as key players, each offering different products and pricing strategies to capture market share. Group 1: Product Offerings and Pricing - Novo Nordisk has launched a higher dose version of Wegovy in the US, priced at $399 for cash customers and about $25 for those with insurance, undercutting Eli Lilly's Zepbound by approximately $100 [1] - Eli Lilly's Zepbound and Mounjaro are viewed as market leaders due to their efficacy, with tirzepatide (Zepbound) being considered the most effective product currently available [4][5] - Novo Nordisk has also introduced a pill version of its product, expected to be available in 2026, expanding its range of injectables [2] Group 2: Market Dynamics and Competition - Efficacy is the primary driver of market share, with Zepbound currently holding a superior position unless a product demonstrates significantly increased effectiveness [5][6] - Eli Lilly is seen as having a strong pipeline of future products, including retatrutide, which may offer higher weight loss percentages and cater to more extreme cases [7][8] - As competition increases, prices are expected to decline, leading to higher demand, particularly among cash-paying consumers who are more price-sensitive [10][12] Group 3: Company Outlooks - Eli Lilly is on a positive outlook due to its growth story, investments in manufacturing and R&D, and improving balance sheet [14][15] - Novo Nordisk is currently rated with a stable outlook, having started with lower leverage compared to Eli Lilly [16] - The injectables are expected to remain the primary treatment method, despite the introduction of pill forms, as they are more effective and have established usage among diabetes patients [18][19] Group 4: Future Developments - Other pharmaceutical companies, such as Amgen and Pfizer, are entering the GLP-1 market with products that may require less frequent dosing, although none currently appear to surpass Zepbound in effectiveness [21][22][23]

Eli Lilly’s Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company said. https://t.co/oS1ZE59Ng7 ...

ICYMI, four new perps markets are now live for trading 💫Costco - COSTDraft Kings - DKNGHims - HIMSEli Lilly - LLYGo long or short with up to 20x leverage. https://t.co/JD3F6dVe1r ...

A new option for millions looking to try those popular weight loss drugs without having to use a needle. The FDA approving Eli Liy's new GLP1 pill called FO set to hit the market next week. Feoo's selling point takes convenience one step further.Unlike WGOi, you don't have to take FO on an empty stomach and then wait 30 minutes to eat or drink. While not as effective as the injections, both pills help people lose weight. Studies show patients who took the highest dose of Fondo lost 12% of their body weight ...

Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions. Patients and consumers may also be winners, as prices fall and selection expands. https://t.co/1upjiYnPww ...

Of course, we were expecting approval for Lilly's product. We're proud to have pioneered this category, both with the injectable form being the first to introduce Wegovy injectable back in 2021 and then being the first to introduce an oral pill form version of whole GOBY. So we're excited about, you know, our benefits for consumers that are in search of medicine for weight loss.The Wegovy pill is highly efficacious. It is 17% weight loss observed with the pill, which is injectable type efficacy. Wegovy is t ...

The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

FDA Approves Eli Lilly’s Weight Loss Pill—Second Weight GLP-1 Drug In Pill Formhttps://t.co/p5uBtpdUYU https://t.co/DyOwW2Tpvb ...

Eli Lilly Chair & CEO Dave Ricks tells CNBC’s Angelica Peebles that with the approval of the company’s GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the globe. Ricks says that while 1 in 10 Americans are currently using a GLP-1, in China only 0.5% of the population has tried one, pointing to a large untapped market opportunity internationally. ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...